×
Diabetes-Exchange Login
Log in with your existing account:
-- Select --
mdBriefCase
AdvancingIn
rxBriefCase
Email Address
Enter Password
Remember Me
Forgot your password?
Home
Register
Log In
Learn
Insulin therapy update: Focus on newer basal insulin analogues
Publications in Practice 2017 – Faster Aspart Series
Interact
Ask the Expert
Explore
Conference Highlights
Latest News
Resources
Diabetes Education: A Comprehensive Review
CDA 2016 updates: Clinical Practice Guidelines
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso 2016 NEJM
CGM Versus FGM. Heinemann 2015. J Diabetes Sci Technol
Coming of age: the artificial pancreas for type 1 diabetes. Thabit 2016. Diabetologia
SGLT2 Inhibitor–associated DiabeticKetoacidosis: Clinical Reviewand Recommendations for Prevention and Diagnosis. Goldenberg 2016. Clinical Therapeutics
Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Bajaj 2016 Variation. Diabetes Care
CDA 2016 updates: Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update.
Menu
Learn
Insulin therapy update: Focus on newer basal insulin analogues
Publications in Practice 2017 – Faster Aspart Series
Interact
Ask the Expert
Explore
Conference Highlights
Latest News
Resources
Diabetes Education: A Comprehensive Review
CDA 2016 updates: Clinical Practice Guidelines
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso 2016 NEJM
CGM Versus FGM. Heinemann 2015. J Diabetes Sci Technol
Coming of age: the artificial pancreas for type 1 diabetes. Thabit 2016. Diabetologia
SGLT2 Inhibitor–associated DiabeticKetoacidosis: Clinical Reviewand Recommendations for Prevention and Diagnosis. Goldenberg 2016. Clinical Therapeutics
Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Bajaj 2016 Variation. Diabetes Care
CDA 2016 updates: Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update.
Footer
About Us
Contact Us
Privacy Policy
Terms of Use
Log In
Forgot Password
Register
×
Featured Poll
Participate today for your chance to win a $25 gift card!
Which of the following do you see as the most significant barrier to insulin pump use in Canada today?
Patient fears of malfunction
Actual risk of malfunction
Complexity of technology
Patient reluctance to be tethered to a device
Insufficient clinical advantage over MDI
DEVOTE Trial Results
Insulin degludec is safe in high-cardiovascular-risk patients with type 2 diabetes, demonstrating non-inferiority to insulin glargine in a landmark cardiovascular (CV) outcomes trial.
Enter Conference Highlights
Insulin therapy update: Focus on newer basal insulin analogues
Kathryn, 24, was diagnosed with type 1 diabetes (T1D) 12 years ago. She is currently enrolled in a Master’s of Education program. Due to the demands of her program, her lifestyle is somewhat erratic. [1 MOC Section 1 credit]
Enter Program
Publications in Practice 2017 – Faster Aspart Series
Publications in Practice topics:
Postprandial Hyperglycemia Trial; Faster aspart clinical pharmacology; Faster aspart in type 1 and 2 diabetes; Faster aspart in an insulin pump setting. [0.25 MOC Section 1 credits per module]
Enter Publications
Current
Ask The Expert
With: Tina Kader, MD, FRCPC, CDE
“Can patients travel safely with an insulin pump?”
View Expert Responses
Conference Highlights
The burden of Type 1 Diabetes and Current Therapies
View More Videos
Featured Resource
CDA 2016 updates: Clinical Practice Guidelines
View Resource